The term diabetic gastroparesis (DGp) has been used to describe a serious complication of diabetes resulting in delayed gastric emptying with associated upper gastrointestinal (GI) symptoms in the absence of any mechanical obstruction. The usual treatments for DGp include nutritional assessment and dietary modifications, glycemic control, prokinetic agents, and antiemetic agents.
DelveInsight's "Diabetic Gastroparesis Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Diabetic Gastroparesis, historical and forecasted epidemiology as well as the Diabetic Gastroparesis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Diabetic Gastroparesis market report also covers emerging drugs, current treatment practices, Diabetic Gastroparesis market share of the individual therapies, current and forecasted Diabetic Gastroparesis Market Size from 2017 to 2030 segmented by seven major markets.
Diabetic Gastroparesis Market Analysis
Among the 7MM, the US is expected to account for the 62% USD of the overall market size of Diabetic Gastroparesis in 2030.
Among the EU-5 countries, Germany accounts for the highest market size for Diabetic Gastroparesis followed by the United Kingdom, Spain, Italy.
The total prevalent population of Diabetic Gastroparesis in the 7MM is expected to rise to 17,859,995 in 2030, during the study period [2017–2030].
Among the Diabetic Gastroparesis patients, females account for a higher number of Diabetic Gastroparesis cases in comparison to males.
The highest prevalent population of Diabetic Gastroparesis among 7MM is in the United States.
According to DelveInsight’s analysis, it has been observed that the prevalence of both T1DM and T2DM associated Diabetic Gastroparesis was highest in the United States.
Diabetic Gastroparesis Market
The Diabetic Gastroparesis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Diabetic Gastroparesis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
Diabetic Gastroparesis Epidemiology
The term diabetic gastroparesis (DGp) has been used to describe a serious complication of diabetes resulting in delayed gastric emptying with associated upper gastrointestinal (GI) symptoms in the absence of any mechanical obstruction. Gastroparesis is a disorder affecting people with both type 1 and type 2 diabetes in which the stomach takes too long to empty its contents (delayed gastric emptying).
The Diabetic Gastroparesis epidemiology section covers insights about historical and current Diabetic Gastroparesis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
Diabetic Gastroparesis Drugs Uptake and Key Market Players
The Diabetic Gastroparesis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Gastroparesis market or expected to get launched in the market during the study period. The analysis covers Diabetic Gastroparesis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Some of the key companies in Diabetic Gastroparesis market include
Allergan
Evoke Pharma
Theravance Biopharma
Censa Pharmaceuticals
CinDome Pharma
And others
For more details visit: https://www.delveinsight.com/report-store/diabetic-gastroparesis-market-size